Lineage, Inc. Common Stock (LINE)vsVentas Inc (VTR)
LINE
Lineage, Inc. Common Stock
$44.34
+4.06%
REAL ESTATE · Cap: $11.18B
VTR
Ventas Inc
$91.98
-5.94%
REAL ESTATE · Cap: $46.72B
Smart Verdict
WallStSmart Research — data-driven comparison
Ventas Inc generates 14% more annual revenue ($6.11B vs $5.36B). VTR leads profitability with a 4.3% profit margin vs -2.7%. VTR earns a higher WallStSmart Score of 51/100 (C-).
LINE
Avoid34
out of 100
Grade: F
VTR
Buy51
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for LINE.
Margin of Safety
-27.4%
Fair Value
$77.05
Current Price
$91.98
$14.93 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Revenue surging 21.9% year-over-year
Areas to Watch
0.4% revenue growth
0.0% earnings growth
Operating margin of 3.3%
Elevated debt levels
Expensive relative to growth rate
ROE of 2.0% — below average capital efficiency
4.3% margin — thin
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : LINE
The strongest argument for LINE centers on Price/Book.
Bull Case : VTR
The strongest argument for VTR centers on Revenue Growth. Revenue growth of 21.9% demonstrates continued momentum.
Bear Case : LINE
The primary concerns for LINE are Revenue Growth, EPS Growth, Operating Margin.
Bear Case : VTR
The primary concerns for VTR are PEG Ratio, Return on Equity, Profit Margin. A P/E of 174.7x leaves little room for execution misses. Thin 4.3% margins leave little buffer for downturns.
Key Dynamics to Monitor
LINE profiles as a turnaround stock while VTR is a growth play — different risk/reward profiles.
VTR is growing revenue faster at 21.9% — sustainability is the question.
LINE generates stronger free cash flow (-55M), providing more financial flexibility.
Monitor REIT - INDUSTRIAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
VTR scores higher overall (51/100 vs 34/100) and 21.9% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Lineage, Inc. Common Stock
REAL ESTATE · REIT - INDUSTRIAL · USA
Lineage, Inc. (Ticker: LINE) is a pioneering biotechnology firm dedicated to regenerative medicine, focusing on next-generation cell therapies targeting ocular diseases, spinal cord injuries, and various cancers. With its proprietary technologies and robust strategic collaborations, Lineage is at the forefront of developing transformative treatment options that aim to improve patient outcomes significantly. The company's commitment to enhancing its diverse product pipeline and expediting clinical trials makes it an attractive investment opportunity for institutional investors seeking exposure in the rapidly evolving healthcare landscape.
Visit Website →Ventas Inc
REAL ESTATE · REIT - HEALTHCARE FACILITIES · USA
Ventas, Inc. is a real estate investment trust specializing in the ownership and management of health care facilities in the United States, Canada and the United Kingdom.
Compare with Other REIT - INDUSTRIAL Stocks
Want to dig deeper into these stocks?